Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer

被引：20

作者：

Kawajiri, Hidemi ^{[1
]}

Takashima, Tsutomu ^{[1
]}

Aomatsu, Naoki ^{[1
]}

Kashiwagi, Shinichiro ^{[1
]}

Noda, Satoru ^{[1
]}

Onoda, Naoyoshi ^{[1
]}

Ishikawa, Tetsurou ^{[1
]}

Hirakawa, Kosei ^{[1
]}

机构：

[1] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Osaka 5458585, Japan

来源：

ONCOLOGY LETTERS | 2014年 / 7卷 / 03期

关键词：

breast cancer; pathological complete response; neoadjuvant chemotherapy; triple-negative subtype; CYCLOPHOSPHAMIDE; DOCETAXEL; THERAPY;

D O I：

10.3892/ol.2014.1792

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of the present retrospective study was to ascertain the significance of pathological complete response (pCR) on overall survival (OS) and disease-free survival (DFS) in each disease subtype of operable breast cancer. Using a single-institution database, 90 patients were identified, who received neoadjuvant chemotherapy (NAC) for operable breast cancer and were eligible for the analysis. In total, 10 patients (11.1%) had succumbed to their diseases and 20 (22.2%) had succumbed to their diseases or exhibited recurrences. The OS of patients with triple-negative (TN) tumors was significantly lower than that of patients with other disease subtypes (P=0.016). The DFS of patients with luminal tumors was higher than that of patients with other subtypes. Survival was improved with pCR following NAC (P=0.044). Across all subtypes, patients who achieved pCR exhibited a higher DFS than patients who did not, but not significantly. pCR only improved OS and DFS in the TN disease subtype (P=0.022 and P=0.048, respectively). pCR following NAC may have prognostic value in TN breast cancer.

引用

页码：663 / 668

页数：6

共 23 条

[1]

[Anonymous], 2008, JAPANESE BREAST CANC, P60

[2] Radiation therapy for brain metastases in breast cancer patients [J].

Aoyama, Hidefumi .

BREAST CANCER, 2011, 18 (04) :244-251

[3] The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27 [J].

Bear, HD ;

Anderson, S ;

Brown, A ;

Smith, R ;

Mamounas, EP ;

Fisher, B ;

Margolese, R ;

Theoret, H ;

Soran, A ;

Wickerham, DL ;

Wolmark, N .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4165-4174

[4] Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen [J].

Buzdar, Aman U. ;

Valero, Vicente ;

Ibrahim, Nuhad K. ;

Francis, Deborah ;

Broglio, Kristine R. ;

Theriault, Richard L. ;

Pusztai, Lajos ;

Green, Marjorie C. ;

Singletary, Sonja E. ;

Hunt, Kelly K. ;

Sahin, Aysegul A. ;

Esteva, Francisco ;

Symmans, William F. ;

Ewer, Michael S. ;

Buchholz, Thomas A. ;

Hortobagyi, Gabriel N. .

CLINICAL CANCER RESEARCH, 2007, 13 (01) :228-233

[5] Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J].

Buzdar, AU ;

Ibrahim, NK ;

Francis, D ;

Booser, DJ ;

Thomas, ES ;

Theriault, RL ;

Pusztai, L ;

Green, MC ;

Arun, BK ;

Giordano, SH ;

Cristofanilli, M ;

Frye, DK ;

Smith, TL ;

Hunt, KK ;

Singletary, SE ;

Sahin, AA ;

Ewer, MS ;

Buchholz, TA ;

Berry, D ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3676-3685

[6] Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study [J].

Colleoni, Marco ;

Giobbie-Hurder, Anita ;

Regan, Meredith M. ;

Thuerlimann, Beat ;

Mouridsen, Henning ;

Mauriac, Louis ;

Forbes, John F. ;

Paridaens, Robert ;

Lang, Istvan ;

Smith, Ian ;

Chirgwin, Jacquie ;

Pienkowski, Tadeusz ;

Wardley, Andrew ;

Price, Karen N. ;

Gelber, Richard D. ;

Coates, Alan S. ;

Goldhirsch, Aron .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) :1117-1124

[7] Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy [J].

Colleoni, Marco ;

Bagnardi, Vincenzo ;

Rotmensz, Nicole ;

Gelber, Richard D. ;

Viale, Giuseppe ;

Pruneri, Giancarlo ;

Veronesi, Paolo ;

Torrisi, Rosalba ;

Cardillo, Anna ;

Montagna, Emilia ;

Campagnoli, Elisabetta ;

Luini, Alberto ;

Intra, Mattia ;

Galimberti, Viviana ;

Scarano, Eloise ;

Peruzzotti, Giulia ;

Goldhirsch, Aron .

BREAST CANCER RESEARCH AND TREATMENT, 2009, 116 (02) :359-369

[8] Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment [J].

Fasching, Peter A. ;

Heusinger, Katharina ;

Haeberle, Lothar ;

Niklos, Melitta ;

Hein, Alexander ;

Bayer, Christian M. ;

Rauh, Claudia ;

Schulz-Wendtland, Ruediger ;

Bani, Mayada R. ;

Schrauder, Michael ;

Kahmann, Laura ;

Lux, Michael P. ;

Strehl, Johanna D. ;

Hartmann, Arndt ;

Dimmler, Arno ;

Beckmann, Matthias W. ;

Wachter, David L. .

BMC CANCER, 2011, 11

[9] Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial [J].

Gianni, Luca ;

Dafni, Urania ;

Gelber, Richard D. ;

Azambuja, Evandro ;

Muehlbauer, Susanne ;

Goldhirsch, Aron ;

Untch, Michael ;

Smith, Ian ;

Baselga, Jose ;

Jackisch, Christian ;

Cameron, David ;

Mano, Max ;

Pedrini, Jose Luiz ;

Veronesi, Andrea ;

Mendiola, Cesar ;

Pluzanska, Anna ;

Semiglazov, Vladimir ;

Vrdoljak, Eduard ;

Eckart, Michael J. ;

Shen, Zhenzhou ;

Skiadopoulos, George ;

Procter, Marion ;

Pritchard, Kathleen I. ;

Piccart-Gebhart, Martine J. ;

Bell, Richard .

LANCET ONCOLOGY, 2011, 12 (03) :236-244

[10] Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer [J].

Jones, Robin L. ;

Salter, Janine ;

A'Hern, Roger ;

Nerurkar, Ash ;

Parton, Marina ;

Reis-Filho, Jorge S. ;

Smith, Ian E. ;

Dowsett, Mitchell .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (02) :315-323

← 1 2 3 →